PRODUCT INFORMATION

SCIO 469

Item No. 29484

CAS Registry No.:	309913-83-5
Formal Name:	6-chloro-5-[[(2R,5S)-4-[(4-fluorophenyl) methyl]-2,5-dimethyl-1-piperazinyl] carbonyl]-N,N,1-trimethyl-α-oxo-1H-indole-3-acetamide
Synonym:	Talmapimod
MF:	$C_{27}H_{30}ClFN_4O_3$
FW:	513.0
Purity:	≥98%
UV/Vis.:	λ_{max}: 256, 313 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SCIO 469 is supplied as a crystalline solid. A stock solution may be made by dissolving the SCIO 469 in the solvent of choice, which should be purged with an inert gas. SCIO 469 is soluble in the organic solvent DMSO.

Description

SCIO 469 is a p38 MAPK inhibitor (IC_{50} = 9 nM for p38α).[1] It is 10-fold selective for p38α over p38β MAPK and 2,000-fold selective over a panel of 20 additional kinases. SCIO 469 inhibits secretion of IL-6 from multiple myeloma patient-derived bone marrow stromal cells (BMSCs) in a concentration-dependent manner. It increases growth inhibition, DNA fragmentation, and caspase-8 and PARP cleavage induced by the proteasome inhibitor PS-341 (bortezomib; Item No. 10008822) in MM.1S cells when used at concentrations of 100 and 200 nM. SCIO 469 (150 and 450 mg/kg) reduces microvessel density and tumor load and increases survival in a 5T33MM murine myeloma model.[2]

References

1. Hideshima, T., Podar, K., Chauhan, D., *et al.* p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. *Oncogene* **23(54)**, 8766-8776 (2004).
2. Vanderkerken, K., Medicherla, S., Coulton, L., *et al.* Inhibition of p38α mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. *Cancer Res.* **67(10)**, 4572-4577 (2007).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/12/2022

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM